Inovio Pharmaceuticals (NASDAQ:INO) Raised to "Sell" at StockNews.com

StockNews.com upgraded shares of Inovio Pharmaceuticals (NASDAQ:INO - Free Report) to a sell rating in a research note published on Friday.

Several other equities analysts have also commented on the stock. Royal Bank of Canada reduced their target price on shares of Inovio Pharmaceuticals from $6.00 to $5.00 and set a "sector perform" rating on the stock in a report on Wednesday, March 19th. JMP Securities reaffirmed a "market outperform" rating and set a $18.00 price objective on shares of Inovio Pharmaceuticals in a research note on Friday, January 10th. Finally, HC Wainwright reissued a "neutral" rating and issued a $3.00 target price on shares of Inovio Pharmaceuticals in a research note on Wednesday, March 19th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $12.20.

Inovio Pharmaceuticals Price Performance

INO stock traded down $0.07 during mid-day trading on Friday, hitting $1.81. 1,027,520 shares of the stock were exchanged, compared to its average volume of 552,256. The business has a fifty day moving average price of $2.04 and a 200 day moving average price of $3.60. Inovio Pharmaceuticals has a 12 month low of $1.74 and a 12 month high of $14.75. The stock has a market capitalization of $47.24 million, a price-to-earnings ratio of -0.45 and a beta of 0.92.

Remove Ads

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last released its earnings results on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, topping analysts' consensus estimates of ($0.87) by $0.18. The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.03 million. As a group, equities analysts forecast that Inovio Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Deep Track Capital LP increased its stake in shares of Inovio Pharmaceuticals by 72.9% during the fourth quarter. Deep Track Capital LP now owns 3,119,162 shares of the biopharmaceutical company's stock valued at $5,708,000 after buying an additional 1,314,796 shares during the period. Stonepine Capital Management LLC bought a new stake in Inovio Pharmaceuticals in the fourth quarter valued at $1,922,000. AIGH Capital Management LLC purchased a new position in Inovio Pharmaceuticals during the 4th quarter valued at $1,197,000. Bank of America Corp DE lifted its position in shares of Inovio Pharmaceuticals by 1,035.2% in the 4th quarter. Bank of America Corp DE now owns 640,987 shares of the biopharmaceutical company's stock worth $1,173,000 after purchasing an additional 584,521 shares during the period. Finally, Highbridge Capital Management LLC bought a new stake in shares of Inovio Pharmaceuticals during the 4th quarter valued at about $549,000. Hedge funds and other institutional investors own 26.79% of the company's stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.